Introduction
Recent research in glioblastoma (GBM) treatment has focused on identification of biomarkers that may predict patient outcome, and may consequently impact therapeutic decisions through selection of more aggressive therapies for tumors with worse prognosis. The impact of clinical factors on patient outcome [1] [2] [3] [4] and the correlation between MR imaging features of GBM and survival [5] [6] [7] [8] [9] [10] [11] have been previously studied. Similarly, the association between genomic biomarkers and patient outcome has received growing attention, in particular with the recent introduction of anti-angiogenetic drugs [12] [13] [14] [15] [16] . Only few studies so far have attempted to integrate clinical factors, imaging biomarkers (usually not evaluated across observers in a standardized fashion), and tumor gene expression data into a statistical model that would potentially provide a robust predictor of patient outcome than each individual type of data [17] . The purpose of our study was to assess whether such a model combining clinical factors, MR imaging features (assessed using standardized semantic imaging features across multiple observers), and genomics would predict patient survival more reliably than any individual data type.
Materials and methods

Study data
Our study was conducted leveraging the TCGA project (http://www.cancergenome.nih.gov/) of the National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI), which aims to catalogue gene mutations associated with cancer. One hundred and two patients with pathology proven GBM were included in this study. Their MR imaging studies were made available through The Cancer Imaging Archive (http://www.cancerimagingarchive.net). Clinical data were obtained from the Open Access Data Tier of the TCGA website, and Health Insurance Portability and Accountability Act of 1996 (HIPAA) de-identified clinical data.
Gene expression, mutation and copy number data were obtained from the TCGA data portal (https://tcga-data.nci.nih.gov). Three sets of genetic metadata were separately considered for the current study:
• genes with P-value < 0.05 in univariate COX model analysis of gene expression and overall survival were assessed further with gene set enrichment analysis (GSEA). GSEA is Please cite this article in press as: Nicolasjilwan Addition of MR imaging features and genetic biomarkers 3 a method to evaluate the expression of genes in the context of pathways. A significant pathway means that gene expression in these pathways is significantly different compared to a random gene set. We used a hypergeometric test to detect significant biological pathways; • the mutation status of specific genes of interest identified in previous work (EGFR, ERBB2, IDH1, NF1, PDGFRA (Table 1) includes 30 semantic descriptors of imaging features of brain tumors clustered by categories pertaining to lesion location, morphology of the lesion substance, morphology of the lesion margin, alterations in the vicinity of the lesion, and extent of tumor resection [7, 19] . For each feature, the scoring system incorporates discrete qualitative, semi-quantitative, or quantitative values, appropriate to the nature of the feature assessed.
Statistical analysis
The 102 study patients were split into a training set of 68 patients and a separate testing set of 34 patients using a stratified sampling method. Stratified sampling was selected because of the small sample size and the skewed survival distribution, and because it ensures an approximately equal survival distribution of subjects between the training and testing data. The split data are also more representative of the population than the random sampling. Samples were sorted by survival in an ascending order. For every three samples, the first two samples were chosen as the training dataset and the third sample was selected as the testing dataset. Models were created in the training dataset and validated in the testing dataset. Associations between survival (outcome) and different individual categories of predictors including clinical variables (Table 2) , imaging features (Table 1) , tumor gene expression, mutation, and copy number variation (Table 3) were assessed using univariate Cox regression models. Clinical, genetic, and imaging data were checked for co-linearity. Non-collinear, predicting variables shown as significant in the univariate Cox regression models were retained and included in several multivariate Cox regression models incorporating the clinical, imaging and/or genomic datasets using stepwise covariate model-building strategies. The models were compared with Akaike's Information Criterion (AIC) to evaluate the model fitness, with the baseline model with clinical data only used as reference for comparisons [20] . A lower AIC value indicates a better model. AUC (area under curve) analysis was also used to measure the accuracy of prediction. A higher AUC value indicates that the model is better at predicting survival. The model using only clinical data was used as the reference. Statistical models were corrected for multiple comparisons using false discovery rate (FDR) procedure.
Results
Study population demographics
The clinical and imaging characteristics of our 102 patients are reported in Tables 2 and 1, respectively. We calculated the association of 17,787 genes with expression data, 10 genes with mutation data and 14 genes with copy number data. The median survival was 324.0 days (25 percentile: 144.5, 75 percentile: 578.8, minimum: 6.0, maximum: 1757.0).
Correlation between clinical variables and survival
Univariate Cox model analyses demonstrated that three clinical variables were significantly correlated to survival with an unadjusted P-value < 0.05 ( Table 2) . These included radiation therapy (P < 0.001), chemotherapy (P < 0.001), and age at initial diagnosis (P = 0.021). The 6 patients who did not receive radiation therapy had a median survival of 66 days compared to median survival of 389 days in the 96 patients with radiation therapy. The 14 patients who did not receive chemotherapy had a median survival of 132 days compared to the median survival of 454 days in the 88 patients with chemotherapy. An increased age at the initial pathological diagnosis was associated with a shorter survival (P = 0.021). All clinical features were used to build survival models in a stepwise fashion. Only chemotherapy was significant in the multiple clinical feature model. Addition of MR imaging features and genetic biomarkers 5 In univariate Cox model analyses, four VASARI features were associated with shorter survival time with an unadjusted P-value < 0.05: higher proportion of enhancing tumor (P = 0.009), higher T1/FLAIR ratio (P = 0.022), and tumor location (P = 0.029) and side (P = 0.049).
Correlation between VASARI imaging features and survival
Only the proportion of tumor enhancing (bolded) was significant in the multiple clinical feature model.
indicates a more infiltrative tumor. Tumor location in the frontal lobe (P = 0.029) and tumors on the right side (P = 0.049) correlated with a longer survival. Only the proportion of enhancing tumor was significant in the multiple clinical feature model ( Fig. 1 ).
Correlation between genomics and survival
Cox model analyses revealed that three genes with copy number variations, PIK3R1 (P = 0.005), AKT1 (P = 0.024), and HRAS (P = 0.071), and two genes with mutation, PDGFRA (P = 0.028) and NF1 (P = 0.082) were associated with survival (Table 3 ). However, none of these genes had FDR (false discovery rate) adjusted P-value < 0.050 [21] .
We used a Cox model analysis to investigate association between survival and tumor gene expression. A total of 724 genes were associated with survival with an adjusted Pvalue < 0.05 in the training dataset; however, none of the genes associated with survival passed the FDR test. Therefore, we carried out a gene set enrichment analysis (GSEA) of the 724 genes in order to select genes in significant biological pathways. This analysis revealed three gene categories Cox model analyses revealed that three genes with copy number variations, PIK3R1 (P = 0.005), AKT1 (P = 0.024), and HRAS (P = 0.071), and two genes with mutation, PDGFRA (P = 0.028) and NF1 (P = 0.082) were associated with survival. The gene set enrichment analysis (GSEA) revealed three gene categories associated with survival with an unadjusted P-value < 0.050. These included: (1) FSHB, FSHR, LHCGR, TSHB, TSHR, PRSS2 genes in Neuroactive ligand-receptor interaction (P = 0.012); (2) LDHAL6A, LDHAL6B, LDHA genes in Cysteine metabolism (P = 0.030); and (3) EFNA5 and EPHA5 genes in Ephrin A reverse signaling (P = 0.009). Only HRAS (bolded) copy number variation was significant in the multiple clinical feature model. associated with survival with an unadjusted P-value < 0.050. These included:
• FSHB, FSHR, LHCGR, TSHB, TSHR, PRSS2 genes in Neuroactive ligand-receptor interaction; • LDHAL6A, LDHAL6B, LDHA genes in Cysteine metabolism; • EFNA5 and EPHA5 genes in Ephrin A reverse signaling.
Only HRAS copy number variation was significantly associated with survival in the multiple genetic feature model.
Multivariate Cox analysis of the association between combined biomarkers and survival
Stepwise multivariate Cox's models were used to assess the association between overall survival time and the clinical data, VASARI imaging features and genomic variations shown as statistically significant in the above-mentioned Cox analyses (Table 4 ). Models were evaluated with AIC values for the model fitness and AUC values for the model prediction power. The clinical variable ''chemotherapy'', the imaging variable ''portion of the tumor enhancing'' and HRAS copy number variation are the only variables that remained significant in the multivariate analysis. The AIC value for the clinical data only model was 744.0 and the one for the clinical and imaging data was 739.8. The AIC value for the clinical and genomic data model was smaller, 569.9, indicating a better model. The AIC value for the clinical, imaging and genomic data was the smallest, 566.7, indicating the best model. AUC analysis led to the same conclusion, supporting the concept that the model including clinical, imaging and genomic data is the best predictor for survival. As designed, we use the testing data to validate the model, AUC analysis led to the same conclusion with the combined model with AUC = 0.679 ± 0.068 comparing to AUC values for chemotherapy = 0.575 ± 0.029, chemotherapy and proportion enhancing = 0.589 ± 0.030, chemotherapy and HRAS = 0.560 ± 0.063. That supports the notion that the model including clinical, imaging and genomic data is the best predictor for survival.
Discussion
Accurate classification of gliomas is important as the treatment modalities are substantially different between WHO grade III and IV tumors. Patients with GBM have the worst prognosis with a median survival of approximately 12 months despite advances in surgery, radiation therapy, and chemotherapy [22] [23] [24] . The current histopathologybased classification system for gliomas is complicated by considerable interobserver variability [25] . Moreover, the existence of different subclasses with varying response to treatment within similar histologic grades of glioma has been shown [25] [26] [27] . Therefore, a classification using more reliable biomarkers has been postulated as a critical element to improve treatment selection and outcome.
The association of clinical variables with the outcome of GBM patients has been extensively studied in the Please cite this article in press as: Nicolasjilwan literature. Among established independent predictors of poor outcome are older age (greater than 60 years), lower Karnofsky Performance Score (KPS), and incomplete tumor resection [1, 3, 4] . Barker et al. [4] also found in a population of 301 GBM patients that a more extensive surgical resection was associated with a better response to radiation therapy. Our univariate analysis demonstrated that three clinical features are associated with survival with a Pvalue < 0.05, including radiation therapy, chemotherapy, and age at initial diagnosis. Multivariate analysis only retained chemotherapy as significantly associated with improved survival. Addition of MR imaging features and genetic biomarkers 9
Several studies have evaluated the prognostic value of the imaging features of GBM. In a recent study of 393 GBM patients by Chaichana et al. [5] , periventricular location of the tumor was associated with worse survival. A retrospective study by Murakami et al. [6] of 79 GBM patients demonstrated that lower ADC values within the tumor correlated with shorter survival. A study by Pope et al. [7] of 15 imaging features of high-grade gliomas, including 41 grade III gliomas and 110 GBMs, demonstrated that the absence of enhancing tumor, the absence of edema and the absence of satellite or multifocal lesions correlated with a doubling of the median survival. In a series of 141 grade III and IV gliomas, Steltzer et al. [9] showed that involvement of the corpus callosum is a poor prognostic sign. In our study, we assessed the prognostic value of a systematic scoring system for the MR imaging features of GBM. Features that were associated with poor outcome on the basis of univariate analyses included the proportion of tumor enhancing, and a higher T1/FLAIR ratio of the tumoral signal abnormality, which corresponds to a more infiltrative tumor. These results are consistent as they include features that likely denote more aggressive tumor behavior. The association of tumoral involvement of the visual cortex with a worse prognosis possibly relates to the fact that this location precludes complete surgical resection. Location of the tumor in the frontal lobe and in the right cerebral hemisphere correlated with longer survival. This may reflect that frontal lobe resection and right hemispheric lesion resection in particular can usually be more extensive than for other locations, as the majority of patients are left hemisphere dominant. The multivariate analysis showed that only the proportion of tumor enhancing significantly correlated with a worse survival. This is concordant with a well-established imaging criterion that associates enhancement with more aggressive tumor behavior [7, 17] . Likewise, surgical biopsies and resections primarily target the enhancing portion of the tumor with the intent to sample and/or resect the higher grade component [28] .
A number of genes among hundreds of currently identified tumor expression genes have been shown to have a predictive value in terms of GBM patient survival [10, 13] . The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in GBM, which allowed a robust gene expression-based molecular classification of GBM into 4 subtypes: proneural, neural, classical, and mesenchymal [12] . Response to aggressive therapy appears to differ by subtype, with the greatest benefit in the classical subtype and no benefit in the proneural subtype. Our multivariate genomic analysis demonstrated that only HRAS copy number variation correlated with poorer survival. The HRAS gene is located on the short (p) arm of chromosome 11. It encodes for a GTPase enzyme also referred to as transforming protein p21, which is involved in regulating cell division in response to growth factor stimulation. HRAS is a proto-oncogene, and HRAS mutations are encountered in bladder, kidney and thyroid cancers (http://ghr.nlm.nih.gov/gene/HRAS). Our finding of HRAS being prognostic of outcome in GBM patients is concordant with several prior reports that demonstrated the causative role of HRAS mutation in the induction of GBM [29] and its association with shorter survival [13] . This gene is not among those used by Verhaak et al. in the tumor gene expression-based classification of GBM [12] and likely plays a role in the genesis of GBM across all subtypes.
The incremental addition of clinical (chemotherapy), imaging (proportion of tumor enhancing) and genomic (HRAS) biomarkers resulted in an incremental increase in the strength of their association with survival. The best model was the one that included all three types of biomarkers. These results are promising as they suggest that the combination of imaging and genomic variables with conventional clinical variables adds significant value in terms of prognosticating outcome.
We acknowledge several limitations to our study. The most significant one is the lack of complete clinical information if our study patients. For instance, Karnofsky Performance Score, percentage of resection, details of the chemotherapy, etc. were not available and could not be incorporated in the statistical analysis.
In conclusion, our study demonstrates that a subset of clinical variables, VASARI imaging features, and tumor gene expression, considered in combination with each other, correlate significantly with GBM patients' survival. These results need to be confirmed in a larger database including more complete clinical information.
